Wednesday, March 5, 2014

Global market for drugs to treat mental disorders to reach nearly $77.1 billion by 2018

Mental disorders such as schizophrenia, mood disorders, substance abuse, and dementia contribute more to global disease burden than cancer or cardiovascular diseases. During the economic downturn of 2009, the global pharmaceutical industry significantly decreased its investment in new treatments for mental disorders, but the improving economic conditions spurred growth in domestic and foreign investment in the field of mental medication. Improvements in patient security policy, rising disease prevalence, and increasing awareness about mental health issues will shape growth in this market for the foreseeable future.                                                            

BCC Research provides an in-depth analysis of the global market for drugs used to treat mental disorders through its report Drugs for Treating Mental Disorders: Technologies and Global Markets. According to the report, this market was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018.

RSS Feeds – Pharmaceuticals

  Use this report to:
  • Gain an overview of the global market for drugs used to treat mental disorders.
  • Analyze global market trends, with data from 2011 and 2012, estimates for 2013, and projections of CAGRs through 2018.
  • Assess information regarding new drug development in the mental health segment, existing products on the market, and a detailed analysis of the competitive environments.
  • Review comprehensive company profiles of major players in this market.

To order your copy of this report (or any of its chapters) or to download the complimentary introduction chapter, click here.

No comments:

Post a Comment

Bookmark and Share